DUAL-LAYER

Two layers of amniotic tissue provides 2x the growth factors

EASY TO USE

Thicker graft facilitates handling in robotic and laparoscopic surgical process

SURGICAL BARRIER

Designed for scar tissue and inflammation reduction potential1

EASY PLACEMENT

Dual layer allows placement of the graft on either side, eliminating orientation restrictions in surgical repair

CHORION FREE

Immune privileged, reducing the risk of adverse

BIOMECHANICAL INTEGRITY

Offers greater tensile strength,
shape manipulation and slower resorption in vivo2

Potential Benefits of Amniotic Membrane Growth Factors:3*

  • null
    Non-Immunogenic
  • null
    Anti-bacterial
  • null
    Anti-inflammatory
  • null
    Tissue regeneration/remodeling
  • null
    Anti-adhesive/anti-scarring
  • null
    Anti-microbial

The placenta contains growth factors and proteins that stimulate the body's own healing mechanism, reducing pain, inammation, and scar tissue4

  • Platelet Derived Growth Factor (PDGF) A & B
  • Transforming Growth Factor beta (TGFβ)
  • Epidermal Growth Factor (EGF)
  • Collagen Types I, III, IV, V, VII
  • Fibronectin
  • Hyaluronic Acid (HA)
  • Vascular Endothelial Growth Factor (VEGF)
  • Fibroblast Growth Factor (FGF)
  • Tissue Inhibitors of Metalloproteinases (TIMPs)
  • Laminin
  • Proteoglycans

Tissue Recovery & Processing

Amniotic Membranes are donated by healthy, pre-screened, consenting women
in the US, and processed in accordance with

TISSUE COLLECTION

Placental tissue is donated from live births in the U.S. without harming the mother or baby

DONOR SCREENING

A thorough medical and social history is obtained for each donor to ensure eligibility requirements are met

INFECTIOUS DISEASE TESTING

  • HBsAg
  • HBcAb
  • HCVAb
  • RPR/STS
  • WNV NAT
  • HCV NAT
  • HBV NAT
  • HIV NAT
  • HIV 1/2Ab
  • HTLV I/II Ab

TISSUE PROCESSING

All tissue undergoes a proprietary cleansing process to remove blood contaminants and reduce bioburden

TISSUE STERILIZATION

Tissue is sterilized for an additional level of safety, achieving a sterility assurance level (SAL) of 10-6

  1. Sinno, Prakash. Plast Surg Int. 2013:146764.
  2. Spoerl, et al. Ophthalmic Res. 2004;36(2):71-7
  3. Martin, et al. Encyclopedia of Reproduction, 2018;3:387-398.
  4. Mamede, et al. Cell Tissue Res. 2012, 349:447–458.

*Based on published studies; not specic to PalinGen Amniotic Membranes